API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

MetasTx

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

MetasTx LLC Raises Funds, Engages J-STAR Research as Manufacturing Partner, and Advances Phase One Development

Details:

The stability and efficacy of MTX-101 (IPA-3), are significantly superior in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer and demonstrate broad applicability across solid tumor cancers.

Lead Product(s): IPA-3

Therapeutic Area: Oncology Product Name: MTX-101

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: J-Star Research

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 07, 2022

ASK
US

Upload
your Marketing & Sales content

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Find Drugs in Development News & Deals for IPA 3

IPA 3